2017 Trends in Medication Management – Cory Cowan
Content Outline
I. Therapy class review 2017
II. Legislative updates
III. Biosimilars
IV. Drug pipeline highlights
Hepatitis C retreatment
Objective
- To determine if products are achieving similar results in real world as in clinical trials
Approach/methods
- Looked at continuously eligible claimants from 2013-2017
- 2nd regimen identified as >=12 week lag from completion of first regimen
Findings
- Retreatment rates higher in 2013-14 (~15%) but for last 2 years <5% and continuing
to decline; newest agents <1% (however, may be due to less follow-up)
Conclusions
- Appears SVR rates have been sustained long-term in clinical practice
- Confirmed benefit for patients and payers
Hepatitis C ongoing surveillance
Potential UPWARD pressure
- Pan-genotypic agents (Epclusa)
- Removal of fibrosis score criterion
- Long-term retreatment potential (Vosevi)
- Expansion to other patient populations (HIV)
- New Focus on Hepatitis B?
Potential DOWNWARD pressure
- Lower cost entrants (Maviret)
- Declining pool of eligible patients
- High SVR rates approaching 100%; low potential for retreatment
- Shorter durations of treatment
The post 2017 Trends in Medication Management – Cory Cowan. appeared first on Health Benefits Hub.